J&J inks a $1.15B dis­cov­ery deal with Pep­tiDream; Medi­vir plots PhI­II HDAC pro­gram

→ Tokyo-based Pep­tiDream has struck a dis­cov­ery deal with J&J worth up to $1.15 bil­lion. In the deal Pep­tiDream will use its plat­form tech to “iden­ti­fy macro­cyclic/con­strained pep­tides against mul­ti­ple meta­bol­ic and car­dio­vas­cu­lar tar­gets of in­ter­est se­lect­ed by Janssen, and to op­ti­mize hit pep­tides in­to ther­a­peu­tic pep­tides or small mol­e­cule prod­ucts.”

→ Swe­den’s Medi­vir says that they’ve gath­ered some pos­i­tive re­sults from a Phase II study of their HDAC in­hibitor remetino­s­tat for cu­ta­neous T-cell lym­phoma. Ear­ly stage pa­tients in the 1% remetino­s­tat gel BID arm had the high­est pro­por­tion of con­firmed re­spons­es (8/20, 40%), in­clud­ing one com­plete re­sponse. The biotech says it is now plan­ning a piv­otal Phase III pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.